Dare Bioscience, Inc. Q3 2025 Earnings Recap

DARE Q3 2025 November 14, 2025

Get alerts when DARE reports next quarter

Daré Bioscience demonstrated strong momentum in Q3 2025, advancing its dual path strategy in women's health while gearing up for the launch of its sildenafil cream, DARE to PLAY, through 503B compounding.

Earnings Per Share Beat

$-0.28 vs $-0.33 est.

+15.2% surprise

Revenue Miss

2262 vs 765000 est.

-99.7% surprise

Market Reaction

1-Day -1.59%

5-Day -9.52%

30-Day -1.59%

See DARE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Anticipated launch of DARE to PLAY Sildenafil Cream by December 2025 marks a significant milestone in women's sexual health, utilizing a 503B outsourcing facility.
Ongoing advancement of clinical programs supported by grant funding, targeting key areas such as contraception and HPV, broadens the company’s innovation pipeline.
Strategy focuses on bridging gaps in women's health by leveraging partnerships and non-dilutive capital, enhancing market reach and operational efficiency.
CEO Sabrina Johnson emphasized the importance of addressing real-world needs and accelerating the transition from discovery to product availability for women's health solutions.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit DARE on AllInvestView.

Next Q1 2026